Effects of Atrial Natriuretic Peptide Infusion and Its Metabolism in Patients with Chronic Renal Failure

抄録

Synthetic α-human atrial natriuretic peptide (hANP) was infused continuously at a rate of 80 ng/kg/min for 20 min into normal volunteers and patients with chronic renal failure (CRF) receiving hemodialysis. Blood pressure (BP) decreased significantly both in normals and in patients with CRF. The magnitude and the duration of the decrease, however, were greater in patients with CRF. The plasma aldosterone concentration (PAC) decreased significantly in normals and only minimally in patients with CRF. The half time (T1/2) of plasma hANP in patients with CRF (M±SE: 4.5±0.5 min) was longer than that in normals (1.8±0.2 min). Moreover, the metabolic clearance rate in patients with CRF (64±7ml/kg/min) was less than in normals (150±20ml/kg/min). Thus, the T1/2 in plasma of hANP in patients with CRF was noticeably longer than in a normal control group. These findings suggest that hANP suppresses PAC regardless of electrocyte imbalances and/or volume change induced by kidney dysfunction and that the kidney may be important in degrading hANP.